Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMX5K4C)

Drug Name
7-methoxytacrine Drug Info
Synonyms
7-Methoxytacrine; 7-Meota; 7-methoxy-1,2,3,4-tetrahydroacridin-9-amine; TA-03; 5778-80-3; BRN 0477401; CHEMBL1256415; 1,2,3,4-Tetrahydro-7-methoxy-9-acridinamine; 9-Amino-7-methoxy-1,2,3,4-tetrahydroacridine; 9-Amino-7-methoxy-1,2,3,4-tetrahydroakridin [Czech]; Acridine, 1,2,3,4-tetrahydro-9-amino-7-methoxy-; 9-Amino-7-methoxy-1,2,3,4-tetrahydroakridin; AC1L3O4H; 9-Acridinamine, 1,2,3,4-tetrahydro-7-methoxy-; 5-22-12-00199 (Beilstein Handbook Reference); SCHEMBL195752; AC1Q582Q; CTK8D9577; MolPort-013-241-798; ZINC6018808
Cross-matching ID
PubChem CID
119053
ChEBI ID
CHEMBL1256415
CAS Number
CAS 5778-80-3
TTD Drug ID
D0S1VV

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mineral absorption 1.87 5.32e-2 48/60 (80%) MT1X;SLC30A1;MT1H;...
RNA degradation 1.65 3.57e-1 53/79 (67.09%) BTG2;TENT4A;LSM6;...
Fanconi anemia pathway 1.64 2.61e-1 36/54 (66.67%) FANCG;BRCA1;RPA3;...
DNA replication 1.62 2.24e-1 34/36 (94.44%) MCM6;FEN1;RFC3;...
Oxidative phosphorylation 1.61 1.97e-1 93/133 (69.92%) COX7B;COX6C;NDUFA1;...
Collecting duct acid secretion 1.57 2.29e-1 22/27 (81.48%) TCIRG1;ATP6V1C1;ATP6V0C;...
Homologous recombination 1.52 3.02e-1 35/41 (85.37%) RBBP8;BRCA1;RPA3;...
Synaptic vesicle cycle 1.48 3.61e-1 63/78 (80.77%) SNAP25;SYT1;CLTB;...
Mismatch repair 1.42 4.84e-1 22/23 (95.65%) MSH2;RFC3;RPA3;...
Epithelial cell signaling in Helicobacter pylori infect... 1.41 4.89e-1 62/70 (88.57%) CXCL8;TCIRG1;HBEGF;...
Glycosphingolipid biosynthesis 1.40 4.48e-1 37/57 (64.91%) ST3GAL5;GLA;B4GALT4;...
Vibrio cholerae infection 1.40 4.42e-1 44/50 (88%) PDIA4;PRKACB;TCIRG1;...
Measles 1.32 7.16e-1 133/139 (95.68%) MX2;CCNE2;CASP8;...
Ovarian steroidogenesis 1.23 8.69e-1 41/51 (80.39%) CYP1B1;ALOX5;INSR;...
Influenza A 1.23 8.38e-1 156/172 (90.7%) HLA-DRA;CXCL8;MX2;...
Ubiquinone and other terpenoid-quinone biosynthesis 1.23 8.08e-1 9/11 (81.82%) NQO1;GGCX;COQ3;...
Proximal tubule bicarbonate reclamation 1.22 7.85e-1 21/23 (91.3%) AQP1;ATP1A1;SLC25A10;...
Type II diabetes mellitus 1.22 7.55e-1 42/46 (91.3%) INSR;CACNA1A;MAPK9;...
Mucin type O-glycan biosynthesis 1.19 8.79e-1 20/36 (55.56%) GALNT7;GALNT12;C1GALT1C1;...
Non-alcoholic fatty liver disease 1.19 8.61e-1 126/155 (81.29%) CXCL8;CASP8;COX7B;...
Phosphatidylinositol signaling system 1.01 8.73e-1 82/97 (84.54%) PIP5K1B;ITPKB;PLCB1;...
Antigen processing and presentation 1.01 8.60e-1 60/78 (76.92%) CD74;HLA-DRA;HLA-DRB1;...
Graft-versus-host disease 1.01 8.64e-1 32/42 (76.19%) HLA-DRA;HLA-DRB1;IL6;...
Parathyroid hormone synthesis, secretion and action 1.00 8.53e-1 98/106 (92.45%) FGFR1;EGR1;SLC34A2;...
Hepatitis C 1.00 8.52e-1 139/157 (88.54%) MX2;CASP8;CLDN7;...
Osteoclast differentiation 1.00 8.54e-1 117/127 (92.13%) ACP5;FOSL2;GAB2;...
ABC transporters 0.99 8.64e-1 37/45 (82.22%) ABCC5;ABCD1;ABCA12;...
Viral protein interaction with cytokine and cytokine re... 0.99 8.66e-1 84/100 (84%) CXCL8;PPBP;IL20RA;...
Nicotinate and nicotinamide metabolism 0.95 8.75e-1 25/35 (71.43%) NAMPT;NMNAT2;SIRT3;...
Calcium signaling pathway 0.95 8.77e-1 213/240 (88.75%) FGFR1;ITPKB;MYLK;...
Galactose metabolism -1.34 3.54e-1 26/31 (83.87%) GALK1;PFKL;SI;...
ECM-receptor interaction -1.35 3.42e-1 80/88 (90.91%) SDC1;THBS4;LAMC1;...
Purine metabolism -1.35 3.46e-1 102/129 (79.07%) PDE6G;ALLC;PDE5A;...
Glioma -1.36 3.31e-1 67/75 (89.33%) CALML3;GADD45B;IGF1R;...
Lysine degradation -1.36 3.40e-1 51/63 (80.95%) PRDM2;CAMKMT;DLST;...
Thyroid hormone synthesis -1.36 3.43e-1 66/75 (88%) FXYD2;TG;PRKACA;...
Primary bile acid biosynthesis -1.38 3.07e-1 15/17 (88.24%) ACOT8;HSD17B4;AKR1D1;...
Systemic lupus erythematosus -1.38 3.17e-1 45/135 (33.33%) TNF;C2;C8A;...
Amoebiasis -1.38 3.27e-1 99/102 (97.06%) LAMC1;SERPINB6;TNF;...
Glutathione metabolism -1.38 3.39e-1 43/57 (75.44%) HPGDS;GSTT1;ODC1;...
Arginine biosynthesis -1.38 3.51e-1 17/22 (77.27%) CPS1;OTC;ASL;...
Pantothenate and CoA biosynthesis -1.45 2.85e-1 14/21 (66.67%) DPYD;ALDH2;ALDH3A2
Amphetamine addiction -1.46 2.77e-1 57/69 (82.61%) PPP3CA;ATF6B;CREB3;...
Phenylalanine metabolism -1.48 2.46e-1 14/17 (82.35%) PAH;DDC;ALDH3B1;...
alpha-Linolenic acid metabolism -1.49 2.55e-1 17/25 (68%) PLA2G3;PLA2G2D;ACOX1;...
Ascorbate and aldarate metabolism -1.49 2.68e-1 15/30 (50%) ALDH9A1;UGT2B17;UGT2B15;...
Arachidonic acid metabolism -1.51 2.45e-1 48/61 (78.69%) AKR1C3;CYP2E1;CYP2C19;...
Arginine and proline metabolism -1.52 2.36e-1 39/50 (78%) MAOB;ODC1;ALDH9A1;...
Biosynthesis of unsaturated fatty acids -1.55 1.74e-1 21/27 (77.78%) ACOX1;HACD1;SCP2;...
Metabolism of xenobiotics by cytochrome P450 -1.56 1.85e-1 49/77 (63.64%) CYP2A6;CYP2E1;GSTP1;...
Valine, leucine and isoleucine degradation -1.56 1.94e-1 42/48 (87.5%) ACADM;BCAT2;BCKDHA;...
Fatty acid elongation -1.61 1.34e-1 19/27 (70.37%) PPT2;HACD1;ELOVL4;...
beta-Alanine metabolism -1.61 1.49e-1 25/30 (83.33%) ALDH6A1;ACOX1;ALDH9A1;...
Steroid biosynthesis -1.61 1.71e-1 19/20 (95%) CYP2R1;CYP51A1;LIPA;...
Drug metabolism -1.63 1.80e-1 78/151 (51.66%) IMPDH2;CYP2A6;CYP2E1;...
Tyrosine metabolism -1.65 1.79e-1 30/36 (83.33%) ADH5;ALDH3A1;TH;...
Retinol metabolism -1.68 1.57e-1 41/68 (60.29%) CYP3A4;RDH8;CYP3A5;...
Linoleic acid metabolism -1.76 9.23e-2 21/29 (72.41%) CYP2E1;CYP2C19;PLA2G3;...
Histidine metabolism -1.82 5.66e-2 16/22 (72.73%) HNMT;ALDH3A1;HAL;...
Fatty acid degradation -1.83 1.13e-1 40/43 (93.02%) ACSL5;ACADM;GCDH;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 3.33uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 3.33uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H